Level A· Stronger Clinical EvidenceSystematic ReviewPubMedOpen access

Therapeutic potential and mechanistic insights into adipose-derived stem cells and mesenchymal stem cell-derived exosomes in patients with Crohn's disease-associated fistulas: challenges and future perspectives.

Sheykhhasan M., Yang P., Yaghoubi SM., Jalise SZ., Poondla N., Narmi MT.

Systematic Review on Autoimmune Research, published in Stem Cell Res Ther (2025) — summary generated from the PubMed abstract.

Open my reading list
Level A· Stronger Clinical EvidenceEvidence level of this study

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Systematic Review
Journal
Stem Cell Res Ther (2025)
Country
England
Reported sample size
—
Source database
PubMed
PMID
41299768
PMCID
PMC12659562
DOI
10.1186/s13287-025-04792-7
Citations
2

Abstract (original English)

Exosomes, as noninvasive biological carriers, have emerged as promising therapeutic agents for a wide range of diseases because of their ability to deliver bioactive molecules and modulate intercellular communication. Their interaction with stem cells (SCs), which naturally secrete regenerative factors, further enhances their therapeutic potential. In particular, the use of adipose-derived stem cells (ADSCs) and exosome-enriched mesenchymal stem cell (MSC) preparations has been explored for treating gastrointestinal (GI) fistulas associated with Crohn's disease (CD), a debilitating form of inflammatory bowel disease (IBD). Preclinical studies, clinical trials, and systematic reviews have evaluated the safety and efficacy of these approaches, with ADSCs-commercially available as Darvadstrocel-emerging as one of the most promising options. While notable progress has been made in both experimental and clinical research, the overall effectiveness of exosomes and stem cell-based therapies is still an area of active investigation. Further studies are needed to develop optimized, innovative treatments with minimal adverse effects. Given the substantial morbidity and healthcare burden associated with IBD-related fistulas, there is a critical need to find cost-effective, accessible, and reliable therapeutic options and strategies. Critically, none of these innovations will reach patient

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

How we grade evidence
HumansCrohn DiseaseExosomesMesenchymal Stem CellsAdipose TissueMesenchymal Stem Cell TransplantationAnimals

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research